The World Health Organization (WHO) declared the 2019–20 coronavirus outbreak a Public Health Emergency of International Concern (PHEIC) on 30 January 2020 and a pandemic on 11 March 2020. Currently, there is no vaccine or specific antiviral treatment for COVID-19. There are multiple attempts in progress to develop such a vaccine.
By April, 115 total vaccine candidates are in early stages of development, with 78 confirmed as active projects, and 37 others announced,
CEPI report says "Phase I-II randomized, interventional trials for dosing and assessment for side effects began in Wuhan, China on the candidate vaccine, Ad5-nCoV (CanSino Biologics, table) and in England on the candidate, ChAdOx1 nCoV-19. Only five other trials on vaccine candidates are in Phase I human testing, as of mid-April."
Clinical trials:
China's CanSino Biologics(Ad5-nCoV) on Phase II interventional trial for dosing and side effects (500). Duration of trilas is March 2020 to December 2020.
ChAdOx1 nCoV-19 (University of Oxford) on Phase I-II, randomized, placebo-controlled, multiple sites (510). Duration of trialsis April 2020 to May 2021.
INO-4800 (Inovio Pharmaceuticals, CEPI), LV-SMENP-DC (Shenzhen Geno-Immune Medical Institute), Covid-19/aAPC (Shenzhen Geno-Immune Medical Institute), mRNA-1273 (Moderna, US National Institute of Allergy and Infectious Diseases) on Phase I (100) trials.
By April, 115 total vaccine candidates are in early stages of development, with 78 confirmed as active projects, and 37 others announced,
CEPI report says "Phase I-II randomized, interventional trials for dosing and assessment for side effects began in Wuhan, China on the candidate vaccine, Ad5-nCoV (CanSino Biologics, table) and in England on the candidate, ChAdOx1 nCoV-19. Only five other trials on vaccine candidates are in Phase I human testing, as of mid-April."
Clinical trials:
China's CanSino Biologics(Ad5-nCoV) on Phase II interventional trial for dosing and side effects (500). Duration of trilas is March 2020 to December 2020.
ChAdOx1 nCoV-19 (University of Oxford) on Phase I-II, randomized, placebo-controlled, multiple sites (510). Duration of trialsis April 2020 to May 2021.
INO-4800 (Inovio Pharmaceuticals, CEPI), LV-SMENP-DC (Shenzhen Geno-Immune Medical Institute), Covid-19/aAPC (Shenzhen Geno-Immune Medical Institute), mRNA-1273 (Moderna, US National Institute of Allergy and Infectious Diseases) on Phase I (100) trials.
Comments
Post a Comment